Program
TQB3473
A development code. Also written as “TQB3473 Tablets”.
In Sino Biopharmaceutical's pipeline, SYK抑制剂
. Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Hematologic Neoplasms, led by Sino Biopharmaceutical.
Furthest: phase 3, since Mar 24, 20253 company-led studies, 2 open or runningNext primary completion: Mar 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 32 open or running | phase 3since Mar 24, 2025 | May 28, 2020 | Mar 2027phase 3 · NCT06900920 |
- Named in Sino Biopharmaceutical’s own pipeline as
TQB3473
, phase 3, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 28, 2020First study: phase 1 study in Hematologic NeoplasmsFirst studyNCT04412577 · 57 enrolled · China
- Mar 24, 2025Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT06900920 · 199 planned · China
- Jul 16, 2025Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT07083739 · 320 planned · China
Ahead
- Mar 2027Primary completion: phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT06900920
- Sep 2027Primary completion: phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT07083739
TargetBeta
“SYK抑制剂”the company's pipeline, read by Claude · source
Other programs on SYK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sovleplenibrule | HUTCHMED | phase 3 | 14 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07083739Purpura, Thrombocytopenic, Idiopathic · China | 2 | Not yet recruiting | Sep 2027 | 320 |
| NCT06900920Purpura, Thrombocytopenic, Idiopathic · China | 3 | Recruiting | Mar 2027 | 199 |
| NCT04412577Hematologic Neoplasms · China | 1 | UNKNOWN | Dec 2021 | 57 |
How it is read
Names in the registry
- “TQB3473 Tablets”, 2 entries
- “TQB3473”, 1 entry
Codes read as this program: TQB3473.
Conditions, from the studies’ own filings
- Purpura, Thrombocytopenic, Idiopathic, 2 studies
- Hematologic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.